The HK1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung adenocarcinoma cell line, with disruption of the HK1 gene encoding hexokinase-1. This heterogeneous knockout pool avoids single-cell cloning, better reflecting genetic variability in tumors. CRISPR-targeted editing leads to loss of functional hexokinase-1 protein, enabling dissection of its roles in glucose metabolism, apoptosis, and cancer biology.
A-549 cells, isolated from a 58-year-old Caucasian male lung adenocarcinoma, are an epithelial model widely used in cancer research, drug metabolism, and respiratory virus studies. They retain features of alveolar type II pneumocytes and provide a well-characterized system for metabolic profiling and functional genomics. The HK1 knockout in this background permits specific interrogation of hexokinase-1 functions without interference from other glycolytic isozymes.
Hexokinase-1 catalyzes the phosphorylation of glucose to glucose-6-phosphate, the first and rate-limiting step in glycolysis. It also binds the mitochondrial VDAC1 channel, interacting directly with BAX and BCL-2 to influence apoptosis. HK1 is regulated by insulin, HIF-1??, c-MYC, p53, and AMPK, linking glucose metabolism to growth, hypoxia, and energy stress signals. Glucose-6-phosphate feeds into glycolysis, the pentose phosphate pathway, and glycogen synthesis. In KRAS-mutant A-549 cells, HK1 sustains glycolytic ATP production; its disruption is expected to shift metabolism and promote mitochondrial-mediated cell death.
In A-549 cells, which display a strong Warburg effect, HK1 knockout provides a model to study metabolic reprogramming in lung adenocarcinoma. Loss of HK1 uncouples glycolysis from mitochondrial VDAC1 interactions, reducing lactate secretion and glycolytic ATP while potentially rerouting glucose-6-phosphate to pentose phosphate pathway or glycogen. This model helps examine compensation by HK2 and reveals dependencies on oncogenic drivers such as mutant KRAS, c-MYC, and HIF-1??. It is valuable for assessing glycolytic inhibitors in a defined genetic context.
Applications include Seahorse metabolic flux analysis, glucose uptake and lactate assays, ATP measurements, and flow cytometry for mitochondrial membrane potential (e.g., TMRM). Standard confirmatory techniques such as Western blot and RT-qPCR validate knockout, while metabolomics profiles glycolytic and pentose phosphate pathway intermediates. Apoptosis assays (annexin V/PI), cell viability under nutrient stress, and drug resistance screening exploit this model to study glycolysis-dependent chemosensitivity. The polyclonal nature supports pooled screening and dose-response studies. For further technical information, contact Ascent Research.
